Method For Preventing Or Treating Osteoporosis Characterized By Administering Teriparatide Or Salt Thereof Twice A Week
Patent No. EP3875105 (titled "Method For Preventing Or Treating Osteoporosis Characterized By Administering Teriparatide Or Salt Thereof Twice A Week") was filed by Asahi Kasei Pharma on Jul 31, 2019. The application was issued on Nov 27, 2024.
Patent Summary
Teriparatide or a salt thereof for preventing or treating osteoporosis in a human patient, characterized by administration of a 28.2 µg unit dose at a frequency of twice a week, with intervals of 2 and 3 days between administrations.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP3875105
- Application Number
- EP19879778A
- Filing Date
- Jul 31, 2019
- Status
- Granted And Under Opposition
- Oct 25, 2024
- Publication Date
- Nov 27, 2024
- External Links
- Slate, Register , Google Patents